Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-03-30
2008-11-11
Saoud, Christine J. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600, C536S023500, C435S069100
Reexamination Certificate
active
07449543
ABSTRACT:
The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.
REFERENCES:
patent: 6222027 (2001-04-01), Kaser et al.
patent: 2004/0086973 (2004-05-01), Duecker
patent: WO 02/16415 (2002-02-01), None
Celano, E. et al. “Selective Regulation of Presynaptic Calcium/Calmodulin-Dependent Protein Kinase II by Psychotropic Drugs”,Biol Psychiatry, Mar. 1, 2003, pp. 442-449, vol. 53, No. 5.
Du, J. et al. “Focus on CaMKII: A Molecular Switch in the Pathophysiology and Treatment of Mood and Anxiety Disorders”,Int J Neuropsychopharmacology, Sep. 2004, pp. 243-248, vol. 7, No. 3.
Consogno, E. et al. “Modifications in Brain CaM Kinase II After Long-term Treatment with Desmethylimipramine”,Neuropsychopharmacology, Jan. 2001, pp. 21-30, vol. 24, No. 1.
Consogno, E. et al. “Long-term Treatment with S-Adenosylmethionine Induces Changes in Presynaptic CaM Kinase II and Synapsin I”,Biol Psychiatry, Sep. 1, 2001, pp. 337-344, vol. 50, No. 5.
Xing, G. et al. “Decreased Prefrontal CaMKII α mRNA in Bipolar Illness”,NeuroReport, Mar. 25, 2002, pp. 501-505, vol. 13, No. 4.
Post, R. M. et al. “Neurobiology of Bipolar Illness: Implications for Future Study and Therapeutics”,Ann Clin Psychiatry, Jun. 2003, pp. 85-94, vol. 15, No. 2.
Chumakov, I. et al. “Genetic and Physiological Data Implicating the New Human Gene G72 and the Gene for D-Amino Acid Oxidase in Schizophrenia”,Proc Natl Acad Sci USA, Oct. 15, 2002, pp. 13675-13680, vol. 99, No. 21.
Williams, M. “Genome-Based Drug Discovery: Prioritizing Disease-Susceptibility/Disease-Associated Genes as Novel Drug Targets for Schizophrenia”,Curr Opin Investig Drugs, Jan. 2003, pp. 31-36, vol. 4, No. 1.
Hemmingsen, R. et al. “Cortical Brain Dysfunction in Early Schizophrenia: Secondary Pathogenetic Hierarchy of Neuroplasticity, Psychopathology and Social Impairment”,Acta Psychiatr Scand Suppl., 1999, pp. 80-88, vol. 395, Abstract only.
Lieberman, J. A. et al. “Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity”,Neuropsychopharmacology, Oct. 1997, pp. 205-229, vol. 17, No. 4.
Colbran, R. J. “Targeting of Calcium/Calmodulin-Dependent Protein Kinase II”,Biochem J., Feb. 15, 2004, pp. 1-16, vol. 378.
Hudmon, A. et al. “Structure-Function of the Multifunctional Ca2+/Calmodulin-Dependent Protein Kinase II”,Biochem J., Jun. 15, 2002, pp. 593-611, vol. 364.
Molnar, M. et al. “mRNA Expression Patterns and Distribution of White Matter Neurons in Dorsolateral Prefrontal Cortex of Depressed Patients Differ from those in Schizophrenia Patients”,Biol Psychiatry, Jan. 1, 2003, pp. 39-47, vol. 53, No. 1.
Wang, H. et al. “Inducible Protein Knockout Reveals Temporal Requirement of CaMKII Reactivation for Memory Consolidation in the Brain”,Proc Natl Acad Sci USA, Apr. 1, 2003, pp. 4287-4292, vol. 100, No. 7.
Zhang, J. et al. “Molecular Cloning and Characterization of a Novel Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor from Human Dendritic Cells”,Biochem Biophys Res Commun, Jul. 13, 2001, pp. 229-234, vol. 285, No. 2.
Schumacher, J. et al. “Examination of G72 and D-Amino-Acid Oxidase as Genetic Risk Factors for Schizophrenia and Bipolar Affective Disorder”,Mol Psychiatry, Feb. 2004, pp. 203-207, vol. 9, No. 2.
Wells, J. A. “Additivity of Mutational Effects in Proteins”,Biochemistry, Sep. 18, 1990, pp. 8509-8517, vol. 29, No. 37.
Ngo, J. T. et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, In:The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Gran (Eds.), Birkhauser: Boston, 1994, pp. 433-506.
Cochran, S. M. et al. “Acute and Delayed Effects of Phencyclidine Upon mRNA Levels of Markers of Glutamatergic and GABAergic Neurotransmitter Function in the Rat Brain”,Synapse, 2002, pp. 206-214, vol. 46.
Lisman, J. et al. “The Molecular Basis of CaMKII Function in Synaptic and Behavioural Memory”,Neuroscience, Mar. 2002, pp. 175-190, vol. 3.
Hudmon, A. et al. “Neuronal Ca2 +/Calmodulin-Dependent Protein Kinase II: The Role of Structure and Autoregulation in Cellular Function”,Annu. Rev. Biochem., 2002, pp. 473-510, vol. 71.
Chang, B. et al. “Characterization of a calmodulin kinase II inhibitor protein in brain”Proceedings of the National Academy of Sciences of the USA, Sep. 1, 1998, pp. 10890-10895, vol. 95, No. 18.
Chang, B. et al. “Calcium/calmodulin-dependent protein kinase II inhibitor protein: localization of isoforms in rat brain”Neuroscience, 2001, pp. 767-777, vol. 102, No. 4.
GenBank Accession No. AF271156, Jun. 11, 2000, p. 1.
Bihain Bernard
Bougueleret Lydie
Bour Barbara
Lockard Jon M
Saliwanchik Lloyd & Saliwanchik
Saoud Christine J.
Serono Genetics Institute S.A.
LandOfFree
Schizophrenia related protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Schizophrenia related protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Schizophrenia related protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4048613